Wall Street analysts expect that Amyris, Inc. (NASDAQ:AMRS) will post ($0.13) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Amyris’ earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.11). Amyris posted earnings of ($0.50) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 74%. The firm is scheduled to report its next earnings results on Thursday, August 5th.
According to Zacks, analysts expect that Amyris will report full-year earnings of ($1.35) per share for the current financial year, with EPS estimates ranging from ($1.39) to ($1.29). For the next fiscal year, analysts forecast that the business will report earnings of ($0.26) per share, with EPS estimates ranging from ($0.38) to ($0.15). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Amyris.
Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Thursday, May 6th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.92). The company had revenue of $176.90 million for the quarter, compared to the consensus estimate of $73.36 million. The firm’s quarterly revenue was up 507.9% compared to the same quarter last year.
In other Amyris news, Director Frank Kung sold 4,678,363 shares of the firm’s stock in a transaction that occurred on Tuesday, April 13th. The shares were sold at an average price of $14.96, for a total transaction of $69,988,310.48. Following the completion of the transaction, the director now owns 2,266 shares of the company’s stock, valued at $33,899.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 44.40% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of the company. Hall Laurie J Trustee grew its holdings in shares of Amyris by 128.7% during the first quarter. Hall Laurie J Trustee now owns 1,990 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 1,120 shares during the last quarter. National Asset Management Inc. grew its holdings in shares of Amyris by 14.6% during the fourth quarter. National Asset Management Inc. now owns 11,800 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 1,500 shares during the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of Amyris by 1.8% during the first quarter. Virtus ETF Advisers LLC now owns 92,257 shares of the biotechnology company’s stock valued at $1,762,000 after buying an additional 1,623 shares during the last quarter. The PNC Financial Services Group Inc. purchased a new stake in shares of Amyris during the first quarter valued at approximately $36,000. Finally, Citigroup Inc. grew its holdings in shares of Amyris by 11.7% during the fourth quarter. Citigroup Inc. now owns 22,449 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 2,351 shares during the last quarter. Hedge funds and other institutional investors own 36.08% of the company’s stock.
AMRS stock traded up $0.18 during trading on Friday, reaching $15.81. The company had a trading volume of 53,570 shares, compared to its average volume of 4,552,202. Amyris has a 52 week low of $1.88 and a 52 week high of $23.42. The stock has a market cap of $4.66 billion, a P/E ratio of -6.28 and a beta of 1.10. The business’s 50 day moving average price is $14.55.
Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets.
Featured Article: Momentum Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.